Vascular access site complications with the use of closure devices in patients treated with platelet glycoprotein IIb/IIIa inhibitors during rescue angioplasty

Catheterization and Cardiovascular Interventions

Volumn 63, Issue 3, 2004, Pages 284-289

  Boccalandro, Fernando ^a   Assali, Abid ^b   Fujise, Kenichi ^a   Smalling, Richard W ^a   Sdringola, Stefano ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Glycoprotein IIb IIIa inhibitors; Manual compression; Rescue angioplasty; Vascular closure devices

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; RETEPLASE; TICLOPIDINE; TIROFIBAN;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; DEVICE; FALSE ANEURYSM; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEMATOMA; HEMOSTASIS; HUMAN; INFECTION; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; RETROPERITONEAL HEMORRHAGE; SAFETY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULAR ACCESS; VASCULAR CLOSURE DEVICE;

AGED; ANEURYSM, FALSE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FEMALE; FEMORAL ARTERY; HEMATOMA; HEMOSTASIS, SURGICAL; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSTHESES AND IMPLANTS; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 8544281637     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20171     Document Type: Article

References (33)

1. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328:673-679.
2. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997;278:2093-2098.
3. Yusuf S, Pogue J. Primary angioplasty compared with thrombolytic therapy for acute myocardial infarction. JAMA 1997;278: 2110-2111.
4. Zahn R, Koch A, Rustige J, Schiele R, Wirtzfeld A, Neuhaus KL, et al. Primary angioplasty versus thrombolysis in the treatment of acute myocardial infarction: ALKK Study Group. Am J Cardiol 1997;79:264-269.
5. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction: ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) investigators. Circulation 1998;98:734-741.
6. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
7. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957-966.
8. Van De WF, Bairn DS. Reperfusion for ST-segment elevation myocardial infarction: an overview of current treatment options. Circulation 2002;105:2813-2816.
9. Antoniucci D, Valenti R, Migliorini A, Moschi G, Trapani M, Buonamici P, et al. Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 2002;89:1248-1252.
10. Cucherat M, Bonnefoy E, Tremeau G. Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction. Cochrane Database Syst Rev 2003;3:CD001560.
11. Juliard JM, Feldman LJ, Golmard JL, Himbert D, Benamer H, Haghighat T, et al. Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-thrombolysis in myocardial infarction (TIMI) time. Am J Cardiol 2003;91:1401-1405.
12. Sundlof DW, Rerkpattanapitat P, Wongpraparut N, Pathi P, Kotler MN, Jacobs LE, et al. Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty. Am J Cardiol 1999;83:1569-1571.
13. Jong P, Cohen EA, Batchelor W, Lazzam C, Kreatsoulas C, Natarajan MK, et al. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction. Am Heart J 2001;141:218-225.
14. Martin U, Kaufmann B, Neugebauer G. Current clinical use of reteplase for thrombolysis: a pharmacokinetic-pharmacodynamic perspective. Clin Pharmacokinet 1999;36:265-276.
15. Tanswell P, Tebbe U, Neuhaus KL, Glasle-Schwarz L, Wojcik J, Seifried E. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 1992;19:1071-1075.
16. Modi NB, Eppler S, Breed J, Cannon CP, Braunwald E, Love TW. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost 1998;79:134-139.
17. Modi NB, Fox NL, Clow FW, Tanswell P, Cannon CP, Van De WF, et al. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol 2000;40:508-515.
18. Kostis JB, Dockens RC, Thadani U, Bethala V, Pepine C, Leimbach W, et al. Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction. Clin Pharmacokinet 2002;41:445-452.
19. Brener SJ, Zeymer U, Adgey AA, Vrobel TR, Ellis SG, Neuhaus KL, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002;39:377-386.
20. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial-IMPACT-AMI investigators. Circulation 1997;95:846-854.
21. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-1914.
22. Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002;360:825-829.
23. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention: EPIC investigators. Circulation 1995;91:2882-2890.
24. Waksman R, King SB III, Douglas JS, Shen Y, Ewing H, Mueller L, et al. Predictors of groin complications after balloon and new-device coronary intervention. Am J Cardiol 1995;75:886-889.
25. Omoigui NA, Califf RM, Pieper K, Keeler G, O'Hanesian MA, Berdan LG, et al. Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVE-AT-I). J Am Coll Cardiol 1995;26:922-930.
26. Muller DW, Shamir KJ, Ellis SG, Topol EJ. Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. Am J Cardiol 1992;69:63-68.
27. Popma JJ, Satler LF, Pichard AD, Kent KM, Campbell A, Chuang YC, et al. Vascular complications after balloon and new device angioplasty. Circulation 1993;88(4 Pt 1):1569-1578.
28. Assali AR, Sdringola S, Moustapha A, Ghani M, Salloum J, Schroth G, et al. Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices. Catheter Cardiovasc Interv 2003;58:1-5.
29. Kornowski R, Brandes S, Teplitsky I, Rechavia E, Shor N, Battler A, et al. Safety and efficacy of a 6 French perclose arterial suturing device following percutaneous coronary interventions: a pilot evaluation. J Invas Cardiol 2002;14:741-745.
30. Kahn ZM, Kumar M, Hollander G, Frankel R. Safety and efficacy of the Perclose suture-mediated closure device after diagnostic and interventional catheterizations in a large consecutive population. Catheter Cardiovasc Interv 2002;55:8-13.
31. Carey D, Martin JR, Moore CA, Valentine MC, Nygaard TW. Complications of femoral artery closure devices. Catheter Cardiovasc Interv 2001;52:3-7.
32. Blankenship JC, Balog C, Sapp SK, Califf RM, Lincoff AM, Tcheng JE, et al. Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials. Catheter Cardiovasc Interv 2002;57:476-483.
33. Applegate RJ, Grabarczyk MA, Little WC, Craven T, Walkup M, Kahl FR, et al. Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularization. J Am Coll Cardiol 2002;40:78-83.